ReviewFrontiers in oncology2022
Current and Emerging Prognostic Biomarkers in Endometrial Cancer.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Prognostic role of C-reactive protein in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- AKR1B1 and AKR1B10 as Potential Prognostic Biomarkers of Endometrial Cancer.International journal of molecular sciences · 2026Article
- Endometrioid Immunohistochemical Prognostic Score Integrating SIRT1, HMGB1, Bcl-2, and Caspase-3 Expression in Endometrioid-Type Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Advances in urinary biomarkers for endometrial cancer detection.British journal of cancer · 2026Review
- Relationship Between Systemic Inflammatory Markers and Histopathological Parameters in Endometrial Adenocarcinoma.Journal of clinical medicine · 2026Article
- Advances in endometrial cancer screening: a comprehensive review of current methods and emerging technologies.International journal of clinical oncology · 2026Review
- Explainable machine learning for preoperative relapse prediction in molecularly stratified endometrial cancer: A single-center finnish cohort study.Computational and structural biotechnology journal · 2026Article
- Clinical Utility of Pan-Immune Inflammation Value (PIV) in Predicting Prognosis of Endometrial Cancer.Journal of clinical medicine · 2025Article
- ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer.Journal of cellular physiology · 2025Article
- Clinicopathological Analysis of a Group of Patients Diagnosed with Endometrial Cancer and Mutation in the Tp53 Gene-Single-Center Study.Journal of clinical medicine · 2025Article
- Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection.British journal of cancer · 2025Article
- Relationship between abnormal p53 expression and high-risk histology in endometrial cancers and living in proximity to hog concentrated animal feeding operations in North Carolina.Gynecologic oncology reports · 2025Article
- Risk factors and prognostic analysis of endometrial cancer with para-aortic lymph node metastasis.Discover oncology · 2025Article
- Expression and prognostic value of EGF-like domain multiple 6 in uterine corpus endometrial carcinoma and its correlation with immune cell infiltration.Scientific reports · 2025Article
- Article
- Real-World Molecular Testing Rates and Patterns in Patients With Primary Advanced or Recurrent Endometrial Cancer in the United States.JCO precision oncology · 2025Article
- Construction of a prognostic model for endometrial cancer related to programmed cell death using WGCNA and machine learning algorithms.Frontiers in immunology · 2025Article
- Immunohistochemistry as a reliable predictor of remission in patients with endometrial cancer: Establishment and validation of a machine learning model.Oncology letters · 2025Article
- A brief review of Lynch syndrome: understanding the dual cancer risk between endometrial and colorectal cancer.Oncology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority present with adverse clinico-pathological characteristics that herald a poor prognosis. Prognostic biomarkers that reliably select those at greatest risk of disease recurrence and death can guide management strategies to ensure that patients receive appropriate evidence-based and personalised care. The Cancer Genome Atlas substantially advanced our understanding of the molecular diversity of endometrial cancer and informed the development of simplified, pragmatic and cost-effective classifiers with prognostic implications and potential for clinical translation. Several blood-based biomarkers including proteins, metabolites, circulating tumour cells, circulating tumour DNA and inflammatory parameters have also shown promise for endometrial cancer risk assessment. This review provides an update on the established and emerging prognostic biomarkers in endometrial cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.